Colofac
In brief
- In many pharmacies Colofac can be purchased over the counter for small packs, though availability varies by country; in Australia it is generally prescription‑only under TGA rules, but some pharmacies and online suppliers do sell Colofac without a prescription—our service offers Colofac without a prescription with delivery across Australia and discreet packaging.
- Colofac (mebeverine) is used for relief of abdominal pain, cramps and bowel irregularity in irritable bowel syndrome (IBS) and other gut spasm conditions; it is an antispasmodic that acts directly on gut smooth muscle to reduce spasms without prominent systemic anticholinergic effects.
- Usual adult dose: 135 mg tablet three times daily, or 200 mg prolonged‑release capsule twice daily.
- Oral administration: standard tablets (135 mg), prolonged‑release capsules (200 mg) and an oral liquid formulation for those with swallowing difficulties.
- Onset of effect is usually within about 30–60 minutes, though individual response may vary.
- Duration of action depends on formulation: immediate formulations provide relief for several hours (typically around 8 hours), while 200 mg prolonged‑release capsules give longer coverage (up to about 12 hours).
- Avoid excessive alcohol while treating IBS—there is no specific severe interaction with moderate alcohol, but alcohol can worsen gastrointestinal symptoms and increase the chance of side effects, so minimise alcohol intake while using Colofac.
- The most common side effects are generally mild and may include headache, dizziness and minor gastrointestinal symptoms such as indigestion, diarrhoea or constipation; allergic skin reactions are possible but rare.
- Would you like to try colofac without a prescription?
Basic Colofac Information
- INN (International Nonproprietary Name): Mebeverine
- Brand Names Available In Australia: Colofac® — tablets 135 mg, blister packs of 30 or 500.
- ATC Code: A03AA04 — drugs for functional gastrointestinal disorders, synthetic anticholinergics.
- Forms & Dosages: Standard tablets 135 mg (1 tablet three times daily); prolonged‑release capsules 200 mg (1 capsule twice daily) and oral liquid formulations exist internationally.
- Manufacturers In Australia: Mylan Australia (part of Viatris) is a listed supplier; originator companies include Abbott/Mylan and international generics producers.
- Registration Status In Australia: Registered with the Therapeutic Goods Administration (TGA) and classified as prescription‑only.
- OTC / Rx Classification: Prescription only in Australia; available OTC in some European/UK markets for small packs.
Critical Warnings & Restrictions
High‑Risk Groups (Elderly, Pregnancy, Chronic Illness)
Mebeverine (Colofac) is contraindicated in patients with known hypersensitivity to mebeverine or any excipients.
Do not supply Colofac to patients with known paralytic ileus or those with hereditary sugar‑intolerance conditions listed in the product information, such as galactose intolerance, Lapp lactase deficiency or glucose‑galactose malabsorption.
Pregnancy and breastfeeding: safety data are limited and insufficient to rule out risk, so avoid use unless a clinician advises it and documents a clear benefit/risk decision.
Severe liver or kidney impairment: clinical data are limited and extreme caution is advised when prescribing or supplying.
Elderly patients can usually take the standard adult dose, but monitor for side effects such as dizziness, faintness or rare cardiovascular effects and review treatment regularly.
- Prescriber/Pharmacist Checklist Before Supply:
- Confirm history of allergy to mebeverine or excipients.
- Ask about symptoms suggesting an acute abdomen (severe pain, fever, vomiting).
- Check pregnancy status and breastfeeding plans.
- Review history of severe liver or kidney disease.
- Review current medications and recent urine drug screening if relevant.
Interaction With Activities (Driving, Workplace Safety Under Australian Law)
Mebeverine is generally well tolerated but may rarely cause dizziness, tiredness or blurred vision.
Advise patients not to drive or operate heavy machinery if they experience dizziness, drowsiness or visual disturbance after taking Colofac.
Employers and workers should report any medicine‑related adverse effects to the workplace safety officer as per local workplace safety guidelines and consider duty limitations until symptoms settle.
Q&A — “Can I Drive After Taking It In Australia?”
Short answer: Usually yes, but if you feel dizzy, sleepy or your vision changes, do not drive.
Report any such symptoms promptly to your GP or pharmacist and follow state road rules regarding driving while impaired.
- Use:
- Take Colofac as prescribed and note any unusual tiredness or dizziness.
- Do not drive if affected; arrange alternative transport.
- Discuss persistent side effects with your GP or pharmacist.
Usage Basics
INN, Brand Names Available In Australia
The International Nonproprietary Name is mebeverine.
In Australia and New Zealand the commonly marketed brand is Colofac® supplied as 135 mg tablets in blister packs of 30 or 500.
Other forms sold elsewhere include 200 mg modified‑release capsules and oral liquid preparations, but the 135 mg tablet is the predominant form in Australia.
Blister packs are the usual retail packaging carried by major chains such as Chemist Warehouse, Priceline and independent community pharmacies.
Legal Classification (TGA‑Approved, PBS‑Listed)
The Therapeutic Goods Administration (TGA) lists mebeverine as a registered prescription‑only medicine in Australia.
Mebeverine is not consistently or universally subsidised on the Pharmaceutical Benefits Scheme (PBS); check the PBS Schedule or local prescriber guidance for the current subsidy status.
- Definitions:
- INN: International Nonproprietary Name — the generic name of the active ingredient.
- Brand: The commercial name such as Colofac®.
- TGA: Therapeutic Goods Administration — regulator for medicines in Australia.
- PBS: Pharmaceutical Benefits Scheme — national subsidy program for approved medicines.
- Common Product Search Terms:
- Colofac 135 mg
- Mebeverine tablets Australia
- Colofac tablets Australia
Dosing Guide
Standard Regimens (PBS Reference Dosing)
The usual adult dose is one 135 mg tablet three times daily.
Internationally a 200 mg modified‑release capsule taken twice daily is used, but the 135 mg tablet is the standard strength available in Australia.
Treatment duration depends on symptom control and may range from several weeks to months under medical supervision.
If there is no improvement after approximately two weeks of treatment, review with the patient’s GP is recommended to reassess diagnosis and management.
Adjustments For Comorbidities
Children: mebeverine is generally not recommended for children under 10 years, as safety and efficacy are not established in this group.
Elderly: routine dose adjustment is usually not required, but monitor clinically for side effects and interactions.
Severe hepatic or renal impairment: no formal dose adjustment is provided, but exercise caution and consider specialist advice where appropriate.
Q&A — “What If I Miss A Dose?”
Take the missed dose as soon as you remember unless it is nearly time for the next scheduled dose.
Do not double up doses to make up for a missed one; this increases the risk of side effects.
- Dosing Options:
- Missed dose remembered soon after: take it straight away.
- Close to the next dose: skip the missed dose and continue regular schedule.
- Unsure: contact your pharmacist or GP for personalised advice.
- When To Seek Review:
- No symptom improvement after 2 weeks.
- Worsening abdominal pain or new alarming symptoms.
- Any severe or allergic side effects.
Interaction Chart
Food And Drinks (Alcohol, Coffee, Australian Diet Context)
No significant food interactions with mebeverine have been documented in product information.
Alcohol may increase the chance of dizziness or general malaise when combined with mebeverine, so advise moderation.
Caffeine from coffee does not interact directly with mebeverine but can aggravate irritable bowel syndrome symptoms in some people.
Common Drug Conflicts
Mebeverine has very few clinically significant drug–drug interactions listed.
Reported rare issues include false positives for amphetamines on some urine drug screens.
No major cytochrome P450 interactions are documented in the available data.
| Substance | Effect | Advice |
|---|---|---|
| Alcohol | May increase dizziness or malaise | Advise moderation; avoid tasks needing alertness if affected |
| Urine Amphetamine Screen | Rare false positive reported | Inform testing service about mebeverine use; confirm with more specific tests |
| CYP Substrate Drugs | No significant interactions documented | Standard monitoring; check specific product information if concerns |
- Check With Your Pharmacist If Taking:
- Antidepressants or other CNS depressants.
- Anticholinergic medicines that may increase side effects.
- Sedatives or strong alcohol use that could add to drowsiness or dizziness.
User Reports & Trends
What do Australian patients say? Many report relief from cramp‑type abdominal pain and quicker symptomatic easing compared with no treatment.
Response varies between individuals and some patients report little or no benefit, which matches international trial heterogeneity.
Tolerability is generally good; reported side effects are mostly mild and rare, such as dizziness, headache or mild gastrointestinal upset.
Pricing and availability strongly influence choice in Australia, with price‑sensitive shoppers comparing major chains and independent pharmacies.
Rural patients increasingly use telehealth and e‑prescriptions, though local stock shortages mean ordering larger blister packs or online delivery is common.
- Common Patient Sentiments:
- “Reduced cramp pain” — frequent comment.
- “Variable response” — effectiveness differs across people.
- “Good tolerability” — side effects uncommon and usually mild.
| Pros | Cons |
|---|---|
| Targets gut spasm without strong anticholinergic effects | Not effective for everyone; modest benefit overall |
| Generally well tolerated | Requires prescription in Australia; cost varies |
- Pharmacist Feedback Checklist:
- Record symptom change and time to improvement.
- Ask about side effects and driving/work impact.
- Note whether patient sought telehealth or local GP for repeat scripts.
Access & Purchase Options
National Chains (Chemist Warehouse, Priceline, TerryWhite)
Colofac is stocked by major Australian pharmacy chains but requires a prescription for supply in line with TGA registration.
Prices vary by pack size and occasional promotions; larger packs tend to offer better value per tablet.
Pharmacy counselling at point of sale will include checking the prescription, advising on dosing and screening for contraindications such as pregnancy or paralytic ileus.
Online Pharmacies And Telehealth E‑Prescriptions
Electronic prescriptions and telehealth consultations commonly result in scripts sent directly to an online or local pharmacy for dispensing.
Verify the TGA registration and prescription requirements before purchase, and confirm delivery times and storage advice for transit, especially in hot Australian summers.
In our online pharmacy, Colofac is available without a prescription, with discreet delivery to Australia in 9‑21 days.
| Source | Pros | Cons |
|---|---|---|
| In‑Store Pharmacy | Immediate counselling, same‑day pickup | May require local GP consult for script |
| Online Pharmacy | Convenient delivery, telehealth integration | Delivery time and cold weather transit considerations |
| Telehealth + E‑Prescription | Fast access to script, can send to chosen pharmacy | Need good internet/phone access; may incur consultation fee |
- Checklist For Purchase:
- Obtain a valid prescription (or use telehealth to get one).
- Confirm pack size and price before ordering.
- Ask about delivery timing and how to store tablets on receipt.
Mechanism & Pharmacology
Simplified Explanation
Mebeverine is an antispasmodic that acts on smooth muscle in the gut to reduce spasm and cramp‑type pain.
It is favoured where traditional anticholinergic side effects are a concern because it does not display prominent systemic anticholinergic activity.
Onset of symptom relief varies between patients and may be noticed within days for some people.
Clinical Terms
The Anatomical Therapeutic Chemical (ATC) code is A03AA04, placing mebeverine among drugs for functional gastrointestinal disorders.
| Lay Term | Clinical Explanation |
|---|---|
| Relieves gut cramps | Reduces smooth muscle spasm in the gastrointestinal tract |
| Gentle on the brain | Minimal systemic anticholinergic effects compared with some antispasmodics |
- Short Definitions:
- Mechanism: Smooth muscle antispasmodic action.
- ATC: A03AA04 — functional GI disorder category.
Indications & Off‑Label Uses
Approved Indications By TGA
TGA‑registered indications include relief of abdominal pain, cramps and bowel irregularity associated with irritable bowel syndrome and non‑specific gut spasm.
Colofac is used as antispasmodic therapy in functional gastrointestinal disorders in line with product information.
Off‑Label Uses In Australian Clinical Practice
Clinicians sometimes use mebeverine for colicky abdominal pain of functional origin or as adjunctive therapy for motility‑related discomfort under supervision.
Mebeverine should not be used for acute severe abdominal pain of unknown origin until structural causes have been excluded.
- Approved Uses:
- IBS‑related cramp and pain relief.
- Non‑specific gut spasm.
- Off‑Label Uses:
- Adjunct in motility‑related discomfort under clinical supervision.
- Red Flags Requiring Immediate Referral:
- Severe persistent pain.
- Fever or signs of systemic infection.
- Blood in stool, unexplained weight loss.
Key Clinical Findings
Randomised controlled trials and systematic reviews internationally report that mebeverine can reduce abdominal cramp pain in some patients with irritable bowel syndrome, though overall effect sizes are modest and study results vary.
Longer‑term safety data are supportive of supervised use and head‑to‑head comparisons with other antispasmodics show mixed results.
Australian prescribing practice follows international evidence combined with clinical experience and patient‑reported outcomes.
| Study Type | Outcome | Level Of Evidence |
|---|---|---|
| Randomised Controlled Trials | Reduction in cramp pain in some participants | Moderate |
| Meta‑Analyses / Systematic Reviews | Modest overall benefit; heterogeneity across studies | Moderate |
| Observational Studies | Good tolerability and patient preference data | Low to Moderate |
- Clinical Takeaways:
- Mebeverine can help selected IBS patients with cramping pain.
- Expect variable response and discuss realistic goals with patients.
- Monitor tolerability and review treatment if no benefit after two weeks.
Alternatives Matrix
PBS‑Listed Alternatives Comparison Table
| Drug | Typical Dose | PBS Status | Main Pros | Main Cons |
|---|---|---|---|---|
| Hyoscine Butylbromide (Buscopan®) | 10–20 mg as required | May be PBS‑listed depending on formulation and indication | Effective antispasmodic for cramps | Anticholinergic effects in some patients |
| Dicycloverine (Dicyclomine) | Typical dosing varies | Varies by formulation | Antispasmodic action | Antimuscarinic side effects |
| Peppermint Oil (Colpermin®) | As per product label | Often OTC | Smooth muscle relaxant; OTC option | Can cause heartburn in some patients |
| Alverine Citrate | As per product label | Varies | Antispasmodic with different profile | Variable availability and evidence base |
Pros And Cons Checklist
- Consider efficacy for cramp relief versus the individual patient response.
- Assess risk of anticholinergic side effects, especially in the elderly.
- Review pregnancy and breastfeeding safety where data are limited.
- Check cost and PBS subsidy status for affordability.
- Consider patient preference for OTC options such as peppermint oil when appropriate.
Common Questions
- How Long Until I Feel Better? Many patients notice relief within days, but review after about two weeks if there is no improvement.
- Is It Addictive? No. Mebeverine is non‑habit forming.
- Can Children Take It? Not generally recommended for children under 10 years; safety and efficacy are not established.
- Pregnancy/Breastfeeding Concerns? Avoid unless a clinician advises use after weighing risks and benefits; limited safety data are available.
- Will Colofac Cause Constipation? Constipation is an uncommon side effect; report persistent or severe bowel changes to your GP.
Price & Access Comparison Table
Comparison Table — Pharmacy/Source, Typical Price Range, PBS Subsidy Status, Prescription Required
| Source | Typical Price Range (30‑Pack / 500‑Pack) | PBS Status | Prescription Required |
|---|---|---|---|
| Chemist Warehouse | Varies by promotion; larger packs better value | Check current PBS listing | Yes |
| Priceline | Varies by store and pack size | Check current PBS listing | Yes |
| Independent Pharmacy | Price varies; may offer bespoke advice | Check current PBS listing | Yes |
| Online Pharmacy | Varies; delivery charges may apply | Check current PBS listing | Yes |
Access Checklist — Major Chains, Online Pharmacies, Rural Vs Urban Availability
- Get a GP consult either in‑person or via telehealth to obtain a prescription if required.
- Confirm the prescription format (electronic or paper) and where you want it sent.
- Choose local pickup or delivery and confirm delivery timing and storage on arrival.
- Store tablets at home below 25°C and out of direct sunlight.
Registration & Regulation
TGA Approval
Colofac (mebeverine) is registered in Australia and classified as a prescription‑only medicine per TGA listings.
Manufacturers and suppliers include Mylan Australia and other global generics producers.
PBS Subsidy Details
Mebeverine is not universally PBS‑listed and subsidy status may change over time.
Prescribers and patients should check the PBS Schedule and local formularies for up‑to‑date subsidy information before prescribing or purchasing.
- Action Steps For Prescribers:
- Check online TGA and PBS registries when choosing a therapy.
- Document indication and rationalise therapy if subsidy is being sought.
Storage & Handling
Household Storage In Australian Climate (Heat/Humidity)
Keep Colofac in its original blister pack and store below 25°C to protect from heat and moisture.
Avoid leaving tablets in cars, bathrooms or other humid or hot places during Australian summers as heat and humidity can degrade the product.
Keep out of reach of children and do not use after the expiry date printed on the pack.
Cold‑Chain Handling For Pharmacies
Colofac is not a cold‑chain medicine but should not be exposed to prolonged heat during transport.
Pharmacies should store stock per manufacturer instructions and advise patients about timing of delivery during hot weather or to opt for collection if delivery will be delayed.
- Patient Storage Checklist:
- Store below 25°C and away from moisture.
- Keep in original blister pack until use.
- Avoid car trunks or direct sunlight during transport.
Guidelines For Proper Use
Australian Pharmacist Counselling Style
Confirm the diagnosis of IBS or functional gut spasm before recommending mebeverine and ensure contraindications such as paralytic ileus or known hypersensitivity are absent.
Explain the usual dosing of 135 mg three times daily and warn patients about rare side effects including dizziness, headache or skin reactions.
Advise patients to stop the medicine and seek medical review for red‑flag symptoms or if there is no benefit after about two weeks.
Document counselling in the patient record and offer written advice where appropriate.
Patient Advice From PBS And National Health Authorities
Encourage patients with IBS to combine medication with diet and lifestyle measures for best results and to consider referral to their GP or a gastroenterologist if symptoms persist or worsen.
Inform patients to seek immediate care for severe pain, fever, signs of systemic illness, or gastrointestinal bleeding.
- Stepwise Counselling Checklist:
- Confirm indication and rule out red flags.
- Explain dose, timing and missed‑dose rules.
- Discuss storage, pregnancy/breastfeeding cautions and when to seek help.
- Patient Handout Template:
- Medicine: Colofac (mebeverine) 135 mg tablets.
- Dosage: One tablet three times daily unless otherwise directed.
- Store: Keep in blister pack below 25°C.
- Side Effects: Dizziness, headache, mild GI upset — stop and seek help for severe reactions.
- When To Seek Help: Severe abdominal pain, fever, blood in stool, persistent vomiting.
Delivery Across Australia
| City | Region | Delivery Time |
|---|---|---|
| Sydney | New South Wales | 9‑14 days |
| Melbourne | Victoria | 9‑14 days |
| Brisbane | Queensland | 9‑14 days |
| Perth | Western Australia | 9‑14 days |
| Adelaide | South Australia | 9‑14 days |
| Canberra | Australian Capital Territory | 9‑14 days |
| Hobart | Tasmania | 9‑14 days |
| Darwin | Northern Territory | 9‑14 days |
| Gold Coast | Queensland | 9‑14 days |
| Newcastle | New South Wales | 9‑14 days |
| Wollongong | New South Wales | 9‑14 days |
| Sunshine Coast | Queensland | 9‑14 days |
| Geelong | Victoria | 9‑14 days |
| Cairns | Queensland | 14‑21 days |
| Townsville | Queensland | 14‑21 days |
Final Notes For Clinicians And Pharmacists
When recommending Colofac, balance modest evidence of benefit against individual patient response and tolerability.
Document counselling, review efficacy at around two weeks, and escalate investigation for any red flags or lack of response.
Remember to check PBS and TGA registries for current subsidy and regulatory details when prescribing or dispensing.
For patients in remote areas, discuss delivery timing and safe storage during transit to preserve product quality.